The importance of developability was brought to full light in a study of 137 clinical-stage & approved mAbs. 12 biophysical properties were found to correlate with clinical success. Approved mAbs have the lowest number of warning flags (left).
It makes the most economical sense to incorporate developability assessment early, preferably in the discovery stage (right). Meanwhile, the varying number of candidates throughout the discovery phase calls for a staged assessment paradigm, where different combinations of in silico or in vitro methods are needed to meet timeline and budget requirements.